IPA (Immunoprecision Antibodies Ltd.) (“IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, announced today BioStrand BV (“BioStrand”), an AI-in-silico discovery subsidiary of IPA, has a research collaboration and license agreement (the “Agreement”) with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company focused on targeted immunotherapies for cancer.
The collaboration will leverage BioStrand’s LENSai software, built on IPA’s proprietary HYFT Universal Fingerprint technologies, and focus on in silico antibody discovery to generate relevant clinical molecules for potential development. Under the terms of the agreement, BioStrand and BriaCell will collaborate on the design, discovery and development of anti-cancer antibodies. Upon successful antibody discovery, BioStrand will receive an upfront payment of $500,000, and will be eligible to receive future success-based development milestones, including those for Investigational New Drug (IND) submissions, clinical milestone payments, and commercial royalties on net product sales. Other conditions are not disclosed.
We are very excited to begin this program with BriaCell and apply our technology to the development of biologics that could have tremendous clinical impact,” said Dr. Ingrid Marken, CEO and co-founder of BioStrand. “When developing highly targeted therapies, it is extremely important to reduce timelines while integrating as much information as possible upstream to improve the efficiency of the process. It is a step toward realizing our long-term vision to make a difference in precision medicine.’
We believe that BioStrand’s revolutionary AI-assisted technology combined with its state-of-the-art protein engineering platform will enable us to develop and discover potent anti-cancer therapeutics,” the company said Miguel A. Lopez-Lago, PhD, Chief Scientific Officer of BriaCell. “This approach would complement BriaCell’s current immunotherapy pipeline of innovative cancer therapeutics.”
Around BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches to cancer treatment. For more information, visit www … BriaCell.com
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several branches in North America and Europe including units such as Talem Therapeutics LLC, Biostrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) BV (collectively the “IPA Family”). The IPA family is a biotherapeutic research and technology group that uses systems biology, multi-omics modeling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized full continuum therapeutic biologics discovery, development and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets.
Forward-Looking Information
This press release contains forward-looking statements as applicable United States Securities Laws and Canadian Securities Laws. Forward-looking statements are often identified by the use of words such as “potential”, “plan”, “expect” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “expects”. does not anticipate” or “believes” or variations of such words and phrases, or states that certain actions, events or results “may”, “could”, “would”, “could” or “will” or “will”. be reached. Forward-looking information contained in this press release includes, but is not limited to, statements regarding the expected impact and results of IPA’s collaboration with BriaCell and statements regarding the amount and timing of payments and commercial royalties that BriaCell will receive. With respect to the forward-looking information contained herein, IPA has provided such statements and information based on certain assumptions that management believed to be reasonable at the time.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements as expressed herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including but not limited to the results of IPA’s collaboration with BriaCell may not be as favorable as anticipated, milestones leading to payments from BriaCell , all may not be achieved, or at all, the level of worldwide net sales giving rise to commercial royalties may be less than anticipated; and those risks discussed in the Company’s annual information form dated July 28, 2022 (which can be viewed under the Company’s profile at www.sedar.com) and the Company’s Form 40-F, dated July 29, 2022 (can be viewed on the company’s profile at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should the assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may differ materially from those expressed or implied by the forward-looking statements contained in this press release. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.
The forward-looking statements contained in this press release are made as of the date of this press release and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether written or oral, made by us or on our behalf from time to time, except as required by applicable law.
Contact:
Tel: 1-888-485-6340
Email: [email protected]
